Patents Assigned to Hubit Genomix, Inc.
-
Publication number: 20240101711Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicants: HUBIT GENOMIX, INC., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Hirohisa SAITO, Kenji MATSUMOTO, Hideaki MORITA, Go ICHIEN, Yasuhiko KOEZUKA, Kimishige ISHIZAKA
-
Publication number: 20240103014Abstract: The present disclosure provides a method of detecting IgG4 and Smad1 in a biological sample from a subject with onset or a risk of onset of diabetic nephropathy.Type: ApplicationFiled: September 22, 2022Publication date: March 28, 2024Applicants: HuBit genomix, Inc., Fuso Pharmaceutical Industries, Ltd.Inventors: Toshio Doi, Tatsuya Tominaga, Go Ichien, Keiichi Yamamoto
-
Publication number: 20210285963Abstract: The present invention provides a test method which enables specific diagnosis of early-stage pathology of diabetic nephropathy. There is provided a method of detecting onset or a risk of onset of diabetic nephropathy, comprising measuring IgG4 in a biological sample derived from a subject. This method may further comprise measuring Smad1 in the biological sample derived from the subject. Preferably, both IgG4 and Smad1 are measured.Type: ApplicationFiled: September 26, 2017Publication date: September 16, 2021Applicants: HuBit genomix, Inc., Fuso Pharmaceutical Industries, Ltd.Inventors: Toshio Doi, Tatsuya Tominaga, Go Ichien, Keiichi Yamamoto
-
Patent number: 10828279Abstract: The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RAR? agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.Type: GrantFiled: April 2, 2019Date of Patent: November 10, 2020Assignees: HUBIT GENOMIX, INC., FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Toshio Doi, Tatsuya Tominaga, Yui Fujita
-
Publication number: 20190314339Abstract: The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RAR? agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.Type: ApplicationFiled: April 2, 2019Publication date: October 17, 2019Applicants: HuBit Genomix, Inc., Fuso Pharmaceutical Industries, Ltd.Inventors: Toshio Doi, Tatsuya Tominaga, Yui Fujita
-
Publication number: 20160333412Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: ApplicationFiled: May 4, 2016Publication date: November 17, 2016Applicants: HUBIT GENOMIX INC.Inventors: Toshio Doi, Hideharu ABE
-
Patent number: 9359645Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 28, 2009Date of Patent: June 7, 2016Assignees: HUBIT GENOMIX INC.Inventors: Toshio Doi, Hideharu Abe
-
Patent number: 7901874Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 9, 2004Date of Patent: March 8, 2011Assignees: Hubit Genomix, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe
-
Patent number: 7862993Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 9, 2004Date of Patent: January 4, 2011Assignees: Hubit Genomix, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe
-
Publication number: 20090324610Abstract: Two genes implicated in arteriosclerotic diseases such as cerebral infarction were successfully identified by performing genome-wide correlation studies using SNPs by targeting the entire genome. Polymorphic mutations that can be used to examine the presence or absence of risk factors for arteriosclerotic diseases were successfully found on the genes. Subjects can be efficiently examined for the presence or absence of risk factors for arteriosclerotic diseases using the presence or absence of the polymorphic mutations as indicators. Furthermore, methods of screening for therapeutic agents for arteriosclerotic diseases are enabled by using expression or function of the genes as index.Type: ApplicationFiled: April 24, 2007Publication date: December 31, 2009Applicants: KYUSHU UNIVERISTY, NATIONAL UNIVERSITY CORPORATION, THE UNIVERSITY TOKYO, HISAYAMA RESEARCH INSTITUTE FOR LIFESTYLE DISEASES, NTT DATA CORPORATION, HUBIT GENOMIX, INCInventors: Yutaka Kiyohara, Mitsuo Iida, Setsuro Ibayashi, Michiaki Kubo, Jun Hata, Yusuke Nakamura, Teruo Omae, Yasuhiro Tanaka, Go Ichien